Adherence to glaucoma medication higher in the mornings

Article

Patient adherence to glaucoma medication could increase with morning application of glaucoma medication.

Patient adherence to glaucoma medication could increase with morning application of glaucoma medication, reveals a paper in the Journal of Glaucoma.

The prospective, randomized crossover treatment trial, conducted by Dr Bryce A. Ford et al., Department of Surgery, Division of Ophthalmology, University of Calgary, Alberta, Canada, involved 30 patients with glaucoma or ocular hypertension.

All patients initially received travoprost eye drops and were randomized to either morning or evening administration for one month. They were then crossed over to the opposite dosing schedule for the second month.

The main outcome measures were adherence between morning versus evening dosing and between first and second month dosing. Patients completed a post-study questionnaire on the convenience of the two dosing schedules.

Patient adherence overall was 89.3% and there was no significant difference between adherence for morning and evening dosing. However, patients claimed to prefer morning administration to evening administration and males were more likely to demonstrate a greater adherence for morning administration.

Adherence decreased from the first month to the second month and IOP response was not significantly affected by morning or evening administration.

The abstract can be read here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.